New and Emerging Strategies to Improve the Diagnosis and Management of Dementia-Related Psychosis (CME/CE Webcast)

Activity Description and Purpose

The prevalence of dementia is increasing rapidly in the United States. Dementia places a burden on affected individuals and caregivers alike. In particular, symptoms of dementia-related psychosis predict reduced quality of life and future institutionalization. Primary care clinicians are uniquely poised to detect and manage these symptoms and to prevent adverse outcomes. In this activity, updated diagnostic guidelines, expert practice recommendations, and current and emerging treatment strategies will be discussed. The desired results of this activity are for clinicians to recognize psychosis as part of the neurodegenerative process in dementia and treat symptoms effectively while maintaining the safety and quality of life of patients.

Target Audience

This educational activity is intended for primary care physicians, nurse practitioners, physician assistants, and nurses caring for patients with dementia-related psychosis (DRP).

Learning Objectives

After completing this activity, participants will be better able to:

  • Discuss strategies for assessment of behavioral and psychological symptoms in persons with dementia
  • Integrate assessment of psychotic symptoms into routine care of persons with dementia
  • Review best practices for diagnosis of DRP
  • Develop evidence-based, safe treatment plans for persons with DRP
  • Describe clinical trial data for emerging treatments for DRP
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Course opens: 
Course expires: 


Larry Culpepper, MD, MPH (Chair)
Professor of Family Medicine
Department of Family Medicine
Boston University School of Medicine
Boston, Massachusetts

Davangere P. Devanand, MBBS, MD
Director, Geriatric Psychiatry
Professor of Psychiatry and Neurology
Columbia University Medical Center
New York, New York

Helen Kales, MD
Professor and Chair
Department of Psychiatry and Behavioral Science
University of California, Davis Health
Sacramento, California

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.


Larry Culpepper, MD, MPH, is a consultant for ACADIA Pharmaceuticals, Inc, Allergan, Eisai Inc, Merck & Co., Inc, and Takeda Pharmaceuticals USA, Inc; and has ownership interest in M-3 Information, LLC.

Davangere P. Devanand, MBBS, MD, is a consultant for ACADIA Pharmaceuticals, Inc; Genentech, Inc; Green Valley; and Sunovion Pharmaceuticals Inc

Helen Kales, MD, has no relevant commercial relationships to disclose

Peer Reviewer Disclosure

Rita Khoury, MD, has no relevant commercial relationships to disclose.

Planners and Managers

MedEdicus planners and managers have no relevant commercial relationships to disclose.  

For Physicians:

Accreditation Statement

imageMedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses:

Interprofessional Joint Accreditation Statement

imageIn support of improving patient care, Amedco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Credit

The maximum number of hours awarded for this Continuing Nursing Education Activity is 1.0 contact hour.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from ACADIA Pharmaceuticals Inc.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Amedco, ACADIA Pharmaceuticals Inc, or FreeCME.

This CME/CE activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 221

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation
Please login or register to take this course.

Clicking Register indicates that you have reviewed the CME/CE information for this activity.